Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
82 pending office actions • 55 clients • 79 examiners • 46 art units • 0 of 82 (0%) have an AI response strategy ready
CHOATE, HALL & STEWART LLP operates in the Biotechnology & Pharmaceuticals technology area with 6132 career applications. The firm currently has 67 pending office actions and a resolved allowance rate of 76.66 percent.
The average of 3.58 office actions per allowance describes the typical path to a patent grant. This statistic is useful for practitioners when forecasting the resources needed for prosecution. The 76.66 percent allowance rate, combined with the 3.58 average office actions, offers a data-grounded expectation for the success and duration of the examination process in the life sciences.
Based on the USPTO statutory response window for each pending office action. 30 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 30 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (1%) |
| §101 + other | 5 (6%) |
| §103 only | 12 (15%) |
| §102 only | 4 (5%) |
| §112 only | 5 (6%) |
| Double-patenting only | 1 (1%) |
| Double-patenting + other | 21 (26%) |
| Multi-statute (no §101) | 32 (39%) |
| No statute on record | 1 (1%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 2 | 23.8% | +56.9% |
| AULAKH, CHARANJIT | 2 | 80.6% | -14.5% |
| FRUMKIN, JESSE P | 2 | 69.9% | +48.7% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| FERGUSON SAMRETH, MARISSA LIANA | 1 | 69.9% | +11.0% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
| KONVES, ADRIANNA N | 1 | 76.2% | +14.8% |
| TRAN, SUSAN T | 1 | 62.8% | +35.1% |
| BOATENG, AFUA BAMFOAA | 1 | 46.6% | +64.4% |
| ZHU, QIN | 1 | 87.4% | +3.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | — |
| 18946253 | ELECTRONIC STETHOSCOPE AND DIAGNOSTIC ALGORITHM | ZHU, QIN | — |
| 18710074 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | AULAKH, CHARANJIT | — |
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800932 | SYSTEMS AND METHODS FOR LIVE FISH TISSUE PRESERVATION | TICHY, JENNIFER M.H. | 81d overdue |
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | ROSENTHAL, ANDREW S | 70d overdue |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | SINGH, ANOOP KUMAR | 53d overdue |
| 18034139 | TRANSDERMAL DELIVERY | BOSWORTH, KAMI A | 49d overdue |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | ROGERS, ERIC JASON | 30d overdue |
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | POPA, ILEANA | 26d overdue |
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | KIM, DANIELLE A | 10d overdue |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | GONZALES, JOSEPHINE MARIA | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219325 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES AT A BINDING INTERFACE | FRUMKIN, JESSE P | 26d overdue |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | GONZALES, JOSEPHINE MARIA | 4d overdue |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | FERGUSON SAMRETH, MARISSA LIANA | — |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | KONVES, ADRIANNA N | — |
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | TRAN, SUSAN T | — |
| 18873573 | NUTRACEUTICAL PARTICLES | BOATENG, AFUA BAMFOAA | — |
| 18216172 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES | FRUMKIN, JESSE P | — |
| Art Unit | Apps |
|---|---|
| 1613 | 3 |
| 1625 | 3 |
| 1632 | 3 |
| 1699 | 2 |
| 1653 | 2 |
| 1629 | 2 |
| 1682 | 2 |
| 1621 | 2 |
| 1638 | 2 |
| 1626 | 2 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | Tract Pharmaceuticals, Inc. | JARRELL, NOBLE E | 1699 | §112 | Final Rejection | — | Pending | Aug 25, 2025 |
| 19283387 | TRANSFER PRINTING STAMPS AND METHODS OF STAMP DELAMINATION | X-Celeprint Limited | FERGUSON SAMRETH, MARISSA LIANA | 2853 | §103 | Non-Final OA | — | Pending | Jul 29, 2025 |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | Helix Nanotechnologies Inc. | GONZALES, JOSEPHINE MARIA | 1631 | §103§112 | Final Rejection | 4d overdue | Pending | Jul 17, 2025 |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | Marvelbiome, Inc. | BREEN, KIMBERLY CATHERINE | 1653 | §101§102§103§112DPOther | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 18989413 | STAMPS FOR MICRO-TRANSFER-PRINTING WITH CURVED STAMP POST ENDS | X-Celeprint Limited | KONVES, ADRIANNA N | §102§103§112Other | Final Rejection | — | Pending | Dec 20, 2024 | |
| 18986536 | ANTI-PATHOGEN COMPOSITIONS | Claw Biotech Holdings, LLC | TRAN, SUSAN T | §102§112Other | Non-Final OA | — | Pending | Dec 18, 2024 | |
| 18873573 | NUTRACEUTICAL PARTICLES | Vitakey Inc. | BOATENG, AFUA BAMFOAA | §103§112 | Non-Final OA | — | Pending | Dec 10, 2024 | |
| 18946253 | ELECTRONIC STETHOSCOPE AND DIAGNOSTIC ALGORITHM | Korion Health Inc. | ZHU, QIN | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2024 | |
| 18883913 | GENERATION OF ACYL AMINO ACIDS | Modular Genetics, Inc. | JONES-FOSTER, ERICA NICOLE | §102§103§112DP | Non-Final OA | — | Pending | Sep 12, 2024 | |
| 18841541 | FOLDABLE PHYSICAL STRUCTURES | University Of Maine System Board Of Trustees | HIJAZ, OMAR F | 3635 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18835307 | CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS | Insight Molecular Diagnostics Inc. | EVANS, ASHLEY ELIZABETH | 3687 | §101 | Final Rejection | — | Pending | Aug 01, 2024 |
| 18728643 | WEARABLES, METHODS, AND SYSTEMS FOR ALERTING USERS TO HEALTH EMERGENCIES | Echas LLC | MINCHELLA, ADAM ZACHARY | 3794 | §102§103§112 | Non-Final OA | 22d | Pending | Jul 12, 2024 |
| 18771086 | ENCLOSED CAVITY STRUCTURES | X-Celeprint Limited | ARROYO, TERESA M | §102§103 | Non-Final OA | — | Pending | Jul 12, 2024 | |
| 18726861 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Lawrence Livermore National Security, LLC | AGGARWAL, SAHIL CHANDER | §112DP | Non-Final OA | — | Pending | Jul 05, 2024 | |
| 18721934 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | RAO, PADMAJA S | §102§103§112DPOther | Non-Final OA | — | Pending | Jun 20, 2024 | |
| 18721531 | RUMINANT FEED OR SUPPLEMENT FOR RUMINANT FEED AND PROCESS FOR PREPARING THE SAME | Borregaard AS | GWARTNEY, ELIZABETH A | 1759 | §103 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18669235 | FORMULATIONS, METHODS, KITS, AND DOSAGE FORMS FOR TREATING ATOPIC DERMATITIS AND FOR IMPROVED STABILITY OF AN ACTIVE PHARMACEUTICAL INGREDIENT | Libertas Bio, Inc. | ROSENTHAL, ANDREW S | 1613 | §103§112 | Final Rejection | 70d overdue | Pending | May 20, 2024 |
| 18710074 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | Hepaitech (Beijing) Biopharma Technology Co., Ltd. | AULAKH, CHARANJIT | 1629 | §112 | Non-Final OA | — | Pending | May 14, 2024 |
| 18654912 | COMPOSITIONS AND METHODS FOR ACCELERATED SOIL STABILIZATION | University Of Maine System Board Of Trustees | GUINO-O UZZLE, MARITES A | §101§102§103§112 | Non-Final OA | — | Pending | May 03, 2024 | |
| 18682205 | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF | Adimab, LLC | VAN DRUFF, SYDNEY | §102§112DP | Non-Final OA | — | Pending | Feb 08, 2024 | |
| 18294825 | CELLULOSE NANOFIBER (CNF) STABILIZED MEMBRANES AND METHODS OF MAKING THEREOF | University Of Maine System Board Of Trustees | ORME, PATRICK JAMES | 1779 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18292859 | IMPROVED CRISPR-CAS TECHNOLOGIES | Sherlock Biosciences, Inc. | HANEY, AMANDA MARIE | 1682 | §102§103DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18291432 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | TheRas, Inc. | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Jan 23, 2024 |
| 18576880 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Olema Pharmaceuticals, Inc. | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18537611 | METHODS AND COMPOSITIONS FOR TREATING AND MANAGING ALZHEIMER'S DISEASE | Pharmatrophix, Inc. | PARK, HAEJIN S | 1614 | §102§103§112DP | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18537754 | SELECTION BY ESSENTIAL-GENE KNOCK-IN | Editas Medicine, Inc. | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 12, 2023 |
| 18532573 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | Calixis Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | 35d | Pending | Dec 07, 2023 |
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | Cavion, Inc. | FETTEROLF, BRANDON J | 1626 | §103DP | Final Rejection | 14d | Pending | Nov 21, 2023 |
| 18389448 | ENERGY STORAGE DEVICES WITH AQUEOUS ELECTROLYTES AND COMPONENTS THEREFOR | Alsym Energy, Inc. | CARVALHO JR., ARMINDO | §102§103DP | Non-Final OA | — | Pending | Nov 14, 2023 | |
| 18560651 | ADENOVIRAL HELPER PLASMID | Forge Biologics, Inc. | BEHARRY, ZANNA MARIA | 1632 | §102§103§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18285810 | MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS | Ensoma, Inc. | WHITEMAN, BRIAN A | 1636 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18284959 | COMPOSITIONS AND METHODS FOR INDOOR AIR REMEDIATION | Neoplants SAS | MCWILLIAMS, KELSEY LYNN | 1663 | §103§112DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18551741 | IMMUNE STIMULATING NANOPARTICLE COMPOSITION | Monta Biosciences Aps | ARNOLD, ERNST V | 1626 | §103DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18277403 | ANTI-PATHOGENIC LIQUID COMPOSITIONS | Claw Biotech Holdings, LLC | KIM, DANIELLE A | 1613 | §101§102§103Other | Final Rejection | 10d overdue | Pending | Aug 16, 2023 |
| 18276110 | NUCLEIC ACID AMPLIFICATION USING PROMOTER PRIMERS | Sherlock Biosciences, Inc. | BAUSCH, SARAE L | 1699 | §102§112 | Non-Final OA | — | Pending | Aug 07, 2023 |
| 18274754 | CANCER THERAPY | Surge Therapeutics, Inc. | YANG, TIAN | 1674 | §103§112 | Non-Final OA | — | Pending | Jul 28, 2023 |
| 18224842 | METHODS OF ALTERING PROTEIN DEPOSITION ON URINARY CATHETERS AND DEVICES | UNIVERSITY OF NOTRE DAME DU LAC | WIECZOREK, MICHAEL P | 1712 | §102§103 | Final Rejection | 26d | Pending | Jul 21, 2023 |
| 18219325 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES AT A BINDING INTERFACE | Pythia Labs, Inc. | FRUMKIN, JESSE P | 1685 | §102 | Final Rejection | 26d overdue | Pending | Jul 07, 2023 |
| 18345163 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami'S Research Laboratory, Pvt. Ltd. | KIM, YUNSOO | 1641 | §103§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18216172 | SYSTEMS AND METHODS FOR ARTIFICIAL INTELLIGENCE-BASED PREDICTION OF AMINO ACID SEQUENCES | Pythia Labs, Inc. | FRUMKIN, JESSE P | §102§112DP | Non-Final OA | — | Pending | Jun 29, 2023 | |
| 18036707 | MACHINE-LEARNED MODELS FOR SENSORY PROPERTY PREDICTION | Osmo Labs, Pbc | BRAHMACHARI, MANDRITA | 2144 | §103 | Non-Final OA | 3d overdue | Pending | May 12, 2023 |
| 18252709 | CANCER DIAGNOSIS AND CLASSIFICATION BY NON-HUMAN METAGENOMIC PATHWAY ANALYSIS | Universal Diagnostics, S.A. | WISE, OLIVIA M. | §101§103§112 | Non-Final OA | — | Pending | May 11, 2023 | |
| 18142068 | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | Olema Pharmaceuticals, Inc. | RODRIGUEZ, RAYNA B | 1628 | DPOther | Non-Final OA | 62d | Pending | May 02, 2023 |
| 18034139 | TRANSDERMAL DELIVERY | Fount Bio, Inc. | BOSWORTH, KAMI A | 3783 | §102§103 | Non-Final OA | 49d overdue | Pending | Apr 27, 2023 |
| 18023909 | MAMMALIAN CELLS AND METHODS FOR ENGINEERING THE SAME | 64-X, Inc. | GROSS, CHRISTOPHER M | 1684 | §102§112Other | Final Rejection | — | Pending | Feb 28, 2023 |
| 18021634 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | Surge Therapeutics, Inc. | POPA, ILEANA | 1633 | §103§112Other | Final Rejection | 26d overdue | Pending | Feb 16, 2023 |
| 18021231 | DEVICES | Sense Biodetection Limited | MUI, CHRISTINE T | 1797 | §102 | Non-Final OA | 30d | Pending | Feb 14, 2023 |
| 18021076 | RESILIENT BIASED LATCH WITH FUSIBLE RETAINING MEMBER | Sense Biodetection Limited | CHIU, MAY LEUNG | 1758 | §102§112 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | Ferring B.V. | HOWARD, ZACHARY C | 1674 | §103Other | Non-Final OA | — | Pending | Dec 09, 2022 |
| 18001340 | GENETIC MODIFICATION | Peter Biotherapeutics, Inc. | LEITH, NANCY J | 1636 | §103 | Non-Final OA | 26d | Pending | Dec 09, 2022 |
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | Marvelbiome, Inc. | REGLAS, GEORGIANA C | 1651 | §112 | Final Rejection | 38d overdue | Pending | Dec 01, 2022 |
| 17982866 | SYSTEMS AND METHODS FOR REAL-TIME MEASUREMENT AND CONTROL OF SPRAYED LIQUID COVERAGE ON PLANT SURFACES | Agzen Inc. | ERDMAN, CHAD G | 2116 | §103 | Non-Final OA | 57d | Pending | Nov 08, 2022 |
| 17923293 | METHODS AND DEVICES FOR TREATMENT OF NEUROPATHY | University Of Maine System Board Of Trustees | PRICE, NATHAN R | 3783 | §102§103 | Final Rejection | — | Pending | Nov 04, 2022 |
| 17980755 | SYSTEMS AND METHODS FOR PREPARING BIOLOGICAL SAMPLES FOR GENETIC SEQUENCING | Universal Diagnostics, S.A. | PHAM, KHAI QUYNH TIEN | 1684 | §103§112 | Final Rejection | 9d | Pending | Nov 04, 2022 |
| 17920385 | COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS | Ned Biosystems, Inc. | WHITE, DAWANNA SHAR-DAY | 1627 | §103DPOther | Final Rejection | — | Pending | Oct 20, 2022 |
| 17761594 | COMPOSITIONS AND METHODS FOR MICROBIOME MODULATION | Washington University | SINGH, SATYENDRA K | 1657 | §103 | Final Rejection | — | Pending | Oct 11, 2022 |
| 17955346 | HIGH-PRECISION PRINTED STRUCTURES AND METHODS OF MAKING | X-Celeprint Limited | POLLEY, CHRISTOPHER M | 1785 | §103 | Non-Final OA | 18d overdue | Pending | Sep 28, 2022 |
| 17914933 | METHODS FOR PRECISE AND BIAS-FREE QUANTIFICATION OF CELL-FREE DNA | Chronix Biomedical | WILDER, CYNTHIA B | 1681 | §102 | Final Rejection | — | Pending | Sep 27, 2022 |
| 17911678 | A TARGETING MODULE COMPRISING PD-L1 AND/OR PD-L2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR MEDIATED IMMUNE RESPONSE IN A MAMMAL | AvenCell Europe GmbH | LEE, YIE CHIA | 1642 | §112 | Non-Final OA | 29d | Pending | Sep 15, 2022 |
| 17908941 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Olema Pharmaceuticals, Inc. | BAUER, NICOLA MARIA | 1621 | §103DP | Non-Final OA | — | Pending | Sep 02, 2022 |
| 17909315 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aleta Biotherapeutics Inc. | O'BRIEN, LEA S | 1646 | §103§112Other | Final Rejection | — | Pending | Sep 02, 2022 |
| 17800932 | SYSTEMS AND METHODS FOR LIVE FISH TISSUE PRESERVATION | Finless Foods Inc. | TICHY, JENNIFER M.H. | 1653 | §101§102§112 | Final Rejection | 81d overdue | Pending | Aug 19, 2022 |
| 17791785 | COMPOSITIONS AND METHODS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND OTHER NEURODEGENERATIVE DISEASES | The Sallie Astor Burdine Breast Foundation | BENZION, GARY | 1681 | §103§112 | Non-Final OA | 15d | Pending | Jul 08, 2022 |
| 17808868 | TEAD INHIBITORS AND USES THEREOF | Cedilla Therapeutics, Inc. | SEAMAN, D MARGARET M | 1625 | §102§112 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17744231 | METHODS FOR DISEASE DETECTION | Universal Diagnostics, S.A. | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Non-Final OA | 29d | Pending | May 13, 2022 |
| 17766113 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | Cavion, Inc. | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | Apr 01, 2022 |
| 17765820 | COMPOSITIONS AND METHODS FOR EXTENDING LIFESPAN | Marvelbiome, Inc. | BREEN, KIMBERLY CATHERINE | 1657 | §103Other | Final Rejection | — | Pending | Mar 31, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | Cancer Research Technology Limited | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17693253 | PRINTING COMPONENTS SUSPENDED BY FRAMES | X-Celeprint Limited | CARLEY, JEFFREY T. | 3729 | §102§103 | Non-Final OA | — | Pending | Mar 11, 2022 |
| 17572403 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | Editas Medicine, Inc. | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | 53d overdue | Pending | Jan 10, 2022 |
| 17503056 | DETECTION AND QUANTIFICATION OF DONOR CELL-FREE DNA IN THE CIRCULATION OF ORGAN TRANSPLANT RECIPIENTS | Chronix Biomedical | KAPUSHOC, STEPHEN THOMAS | 1683 | §103§112DP | Final Rejection | 107d overdue | Pending | Oct 15, 2021 |
| 17599673 | FORMULATIONS | Synchroneuron Inc. | PALENIK, JEFFREY T | 1615 | §103 | Non-Final OA | — | Pending | Sep 29, 2021 |
| 17412608 | CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY | Editas Medicine, Inc. | BABIC, CHRISTOPHER M | 1633 | §103DP | Final Rejection | — | Pending | Aug 26, 2021 |
| 17366830 | CANCER THERAPY | Ned Biosystems, Inc. | TRAN, ERIC | 1629 | §103§112 | Non-Final OA | — | Pending | Jul 02, 2021 |
| 17297493 | IMPROVED DELIVERY OF LARGE AGENTS | Eirion Therapeutics, Inc. | FUBARA, BLESSING M | 1613 | §112DP | Non-Final OA | — | Pending | May 27, 2021 |
| 17274948 | PLASMINOGEN ACTIVATOR INHIBITOR 1 (PAI-1) INHIBITORS AND USES THEREFOR | Eirion Therapeutics, Inc. | MCANANY, JOHN D | 1625 | §102§103§112DP | Non-Final OA | — | Pending | Mar 10, 2021 |
| 17267299 | PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES | Kernal Biologics, Inc. | EBBINGHAUS, BRIANA NOEL | 1632 | §102 | Final Rejection | — | Pending | Feb 09, 2021 |
| 17251447 | REVERSED UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS FOR TARGETING OF DIVERSE MULTIPLE ANTIGENS AND METHOD OF MANUFACTURING THE SAME AND USE OF THE SAME FOR TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | AvenCell Europe GmbH | COOK, LISA V | 1642 | §103§112DP | Non-Final OA | — | Pending | Dec 11, 2020 |
| 16979515 | DISPERSANT AND BINDER FOR LITHIUM ION BATTERIES BASED ON MODIFIED LIGNIN AND CARBOXYMETHYL CELLULOSE | Borregaard AS | MARTIN, ANGELA J | 1727 | §103§112 | Final Rejection | 14d | Pending | Sep 09, 2020 |
| 16651911 | FORMULATIONS | Intellia Therapeutics, Inc. | BURKHART, MICHAEL D | 1638 | §102§103 | Final Rejection | — | Pending | Mar 27, 2020 |
| 16806536 | RECEPTACLES FOR STAINING AND/OR RINSING SAMPLES AND METHODS OF THEIR USE | Samantree Medical (Switzerland) SA | KUMAR, RAKESH | 3651 | §103§112 | Final Rejection | 3d overdue | Pending | Mar 02, 2020 |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | Chronix Biomedical | SITTON, JEHANNE SOUAYA | 1682 | §112DP | Non-Final OA | 44d overdue | Pending | Feb 25, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial